Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25892145

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 May
First author
Machiels JP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 May;16(5):488-9. doi: 10.1016/S1470-2045(15)70178-6.
    note
    Source null
    related pmid
    25892143
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Jul;12(7):373. doi: 10.1038/nrclinonc.2015.86.
    note
    Source null
    related pmid
    25940985
    relationship
    Comment in

Authors and identifiers

  1. name
    Machiels JP
    type
    Author
  2. name
    Haddad RI
    type
    Author
  3. name
    Fayette J
    type
    Author
  4. name
    Licitra LF
    type
    Author
  5. name
    Tahara M
    type
    Author
  6. name
    Vermorken JB
    type
    Author
  7. name
    Clement PM
    type
    Author
  8. name
    Gauler T
    type
    Author
  9. name
    Cupissol D
    type
    Author
  10. name
    Grau JJ
    type
    Author
  11. name
    Guigay J
    type
    Author
  12. name
    Caponigro F
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Machiels JP
    type
    Author
  2. name
    Haddad RI
    type
    Author
  3. name
    Fayette J
    type
    Author
  4. name
    Licitra LF
    type
    Author
  5. name
    Tahara M
    type
    Author
  6. name
    Vermorken JB
    type
    Author
  7. name
    Clement PM
    type
    Author
  8. name
    Gauler T
    type
    Author
  9. name
    Cupissol D
    type
    Author
  10. name
    Grau JJ
    type
    Author
  11. name
    Guigay J
    type
    Author
  12. name
    Caponigro F
    type
    Author
bibliography ids
  1. nci-bib-69f5a1e454c06d36a7578c48
book metadata
content sha256
d1ee5ee23469b5f9e2a7b15fe8392005cfb90e28b631f77ae794cb393aa8842d
document type
citation
dois
  1. 10.1016/S1470-2045(15)70124-5
electronic publication date
display
2015 Apr 16
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:25892145
immutable id
pubmed:25892145@d1ee5ee23469b5f9e2a7b15fe8392005cfb90e28b631f77ae794cb393aa8842d
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
583-94
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 May;16(5):488-9. doi: 10.1016/S1470-2045(15)70178-6.
    note
    Source null
    related pmid
    25892143
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Jul;12(7):373. doi: 10.1038/nrclinonc.2015.86.
    note
    Source null
    related pmid
    25940985
    relationship
    Comment in
outcomes validated
false
pmid
25892145
provenance
batch id
74265f1b641f04cf2d05
provider
NCBI PubMed ESummary
record sha256
97081bf5fd8cdbdc7ce23e9533114e6aff25a3f5b2e411f8f9d150ca2d87a8aa
response sha256
193df6bb6d2ac41af73dc445bf8171fe8076a8c8a5e98882a3d6a1ada428b0f0
retrieved at
2026-09-09T23:47:10.134322+00:00
publication date
display
2015 May
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25892145/
title
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Preserved source evidence · Not medical advice